Contineum Therapeutics (CTNM) Total Current Liabilities (2023 - 2026)

Contineum Therapeutics' Total Current Liabilities history runs 4 years deep, the most recent figure standing at $6.5 million for Q2 2026.

• In Q2 2026, Total Current Liabilities fell 9.54% year-over-year to $6.5 million; the TTM figure through Jun 2026 stood at $6.5 million (down 9.54% YoY), while the FY2025 annual figure was $9.7 million, down 2.31% from the prior year.
• Total Current Liabilities for Q2 2026 stood at $6.5 million, down from $6.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $10.0 million in Q4 2024, with the low at $3.7 million in Q2 2024.
• The 4-year median for Total Current Liabilities is $6.5 million (2026), against an average of $7.0 million.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities surged 92.94% in 2025, then dropped 25.61% in 2026.
• Contineum Therapeutics' Total Current Liabilities stood at $5.5 million in 2023, then surged by 81.87% to $10.0 million in 2024, then declined by 2.31% to $9.7 million in 2025, then plunged by 33.03% to $6.5 million in 2026.
• Business Quant data shows CTNM's Total Current Liabilities at $6.5 million in Q2 2026, $6.7 million in Q1 2026, and $9.7 million in Q4 2025.